RT Journal Article
T1 Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy
A1 Tamargo Menéndez, Juan
A1 Caballero Collado, Ricardo
A1 Gómez García, Ricardo
A1 Núñez Fernández, Lucía
A1 Vaquero González, Luis Miguel
A1 Delpón Mosquera, María Eva
AB Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are the most effective and best-tolerated drugs to treat elevated levels of low-density lipoprotein cholesterol (LDL-C). In addition, they exhibit other effects unrelated to their lipid lowering effects (pleiotropic actions). In recent years, experimental and clinical evidence demonstrates that statins exert antiarrhythmic properties, reducing the recurrences of supraventricular and life-threatening ventricular arrhythmias both in patients with and without coronary artery disease (CAD). Thus, statins may constitute a novel therapeutic approach to cardiac arrhythmias. This article reviews the antiarrhythmic properties of statins as well as the possible mechanisms involved, including the lowering of LDL-C levels, the improvement of endothelial dysfunction and autonomic function, the stabilization of the atherosclerotic plaques, the antioxidant, antiinflammatory, antithrombotic and cardioprotective properties and the modulation of transmembrane ion fluxes.
PB Elsevier
SN 0163-7258
YR 2007
FD 2007
LK https://hdl.handle.net/20.500.14352/92738
UL https://hdl.handle.net/20.500.14352/92738
LA eng
NO Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther. 2007 Apr;114(1):107-26. doi: 10.1016/j.pharmthera.2006.12.002. Epub 2006 Dec 29. PMID: 17287023
NO Comisión Interministerial de Ciencia y Tecnología (España)
NO Ministerio de Sanidad y Consumo (España)
NO Instituto de Salud Carlos III
NO Fundación Mutua Madrileña
DS Docta Complutense
RD 7 abr 2025